Clare Sansom

Clare Sansom

Clare Sansom studied physics and then biophysics at the University of Bristol, UK, graduating with a Ph.D. in 1987.

She held postdoctoral positions in structure-based drug discovery at the Universities of Aston and Leeds, UK and at the National Cancer Institute, Frederick USA where she studied HIV protease inhibition. She left frontline research in the late 90s for a portfolio career; she teaches medicinal chemistry at the UK’s Open University and bioinformatics at Birkbeck College, London, both to MSc level and works as a freelance science writer and editor. Recent clients besides the RSC include the New York Academy of Sciences and the Lancet monthly journals

  • Deal or no deal - Hero

    Deal or no deal?

    17 February 2017

    Clare Sansom highlights recent changes in the landscape of pharma company collaborations and acquisitions

  • 7/7 London bombings - Hero image

    Separating the guilty and the innocent

    20 October 2016

    Chromatography is one of the key weapons in the forensic scientist’s arsenal, as Clare Sansom discovers

  • CW0316_Ribozyme_F1_title_630m

    When is an enzyme not a protein?

    29 February 2016

    When it’s a ribozyme. Clare Sansom reports

  • CW0915_Feature_DataMining_Fig1_630m

    Exploiting the data mine

    13 August 2015

    Chemists must embrace open data to allow us to collectively get the best out of the masses of new knowledge we unearth, reports Clare Sansom

  • CW0415_Feature_Disease_F1_630m

    Combating rare diseases

    26 March 2015

    Developing drugs for treating rare diseases isn’t always financially viable. Clare Sansom looks at some recent success stories

  • Map and Geiger counter

    Cleaning up after Fukushima

    27 November 2014

    Chemistry is playing a vital role in helping remove radioactive material from the environment after the 2011 disaster. Clare Sansom reports

  • Rubisco diffraction pattern

    Life in the freeze frame

    26 August 2014

    Using x-rays to probe biological molecules has revolutionised science. Clare Sansom looks at a century of progress

  • old diffractometer

    Crystal clear

    13 December 2013

    With the international year of crystallography upon us, Clare Sansom celebrates this important discipline

  • animals at a vet

    Animal pharm

    30 July 2013

    Making drugs to treat animals is potentially lucrative – but also difficult, as Clare Sansom discovers

  • hands and molecule

    People power

    30 January 2013

    Harnessing the wisdom – and money – of crowds has rocketed in popularity in recent years. Clare Sansom looks at whether chemistry can join the gang

  • 0912CW_FEATURE_TBDrugs_Fig1_630

    The latent threat of tuberculosis

    15 August 2012

    Although TB was close to being eradicated in the developed world, it is a major problem in developing countries. With drug-resistant strains on the increase, Clare Sansom outlines the latest in the fight against this killer disease

  • Feature

    Climbing the data mountain

    22 December 2011

    Clare Sansom takes a 'peak' at the databases that stop researchers being buried under an avalanche of chemical information

  • Feature

    Turning the tables on Alzheimer's

    30 June 2011

    As our understanding of Alzheimer's disease develops, Clare Sansom takes a look at emerging strategies for treating this enigmatic illness

  • Feature

    Fighting the flu

    31 January 2011

    The threat of pandemic influenza is constantly on the horizon. Clare Sansom explores the latest attempts to tackle an ever-changing foe

  • Feature

    Receptive receptors

    30 July 2010

    One route to developing new drugs is to look at targeting the hundreds of G-protein-coupled receptors that are not currently exploited clinically. Clare Sansom investigates

  • Feature

    Model molecules

    31 March 2010

    As computational chemistry's footprint expands, Clare Sansom considers the technical challenges that remain

  • Feature

    Molecules made to measure

    28 October 2009

    HIV protease inhibitors have been one of the big successes of rational drug design. Clare Sansom looks at the impact of structural biology on drug discovery

  • Feature

    Temozolomide - birth of a blockbuster

    26 June 2009

    The history of anticancer drug temozolomide can be traced back over 30 years - and it all started with some novel nitrogen chemistry, says Clare Sansom

  • Feature

    Structuring Europe

    27 November 2008

    Not every country in Europe can afford a synchrotron. So as new member states join, how is EU funding getting the best out of research across the continent? Clare Sansom reports